Table 4 Mitochondrial respiration changes
SHAM-Placebo (N = 12) | HBOT (N = 10) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Baseline | SHAM | 3 months | Baseline | Post-HBOT | 3 months | Baseline Comparison P value | Net effect size | ANCOVA (P) | |
P-value | P value | ||||||||
Primary endpoint | |||||||||
Leak [pmol /(s*mg)] | 8.51 ± 3.26 | 7.34 ± 3.92 | 0.15 | 9.72 ± 1.90 | 11.98 ± 5.60 | 0.17 | 0.32 | 0.429 [− 0.47–1.33] | 3.80 (0.06) |
Complex I (Pyruvate–Malate–Glutamate) [pmol /(s*mg)] | 43.14 ± 16.03 | 35.21 ± 16.37 | 0.03 | 58.05 ± 16.05 | 63.75 ± 19.99 | 0.21 | 0.04 | 1.120 [0.160–2.080] | 7.31 (0.01) |
Complex II (uncoupled) [pmol /(s*mg)] | 44.03 ± 13.13 | 46.32 ± 10.10 | 0.49 | 61.32 ± 14.39 | 63.19 ± 14.40 | 0.65 | 0.008 | 1.223 [0.250–2.195] | 2.19 (0.15) |
Maximal coupled capacity (Succinate) | 74.78 ± 20.40 | 72.22 ± 21.23 | 0.66 | 97.85 ± 22.21 | 105.56 ± 21.61 | 0.26 | 0.019 | 1.085 [0.129–2.041] | 4.89 (0.04) |
[pmol /(s*mg)] Maximal uncoupled capacity [pmol /(s*mg)] | 87.94 ± 22.99 | 80.36 ± 23.81 | 0.24 | 117.30 ± 37.96 | 121.49 ± 29.51 | 0.56 | 0.036 | 0.956 [0.013–1.898] | 6.04 (0.02) |